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Streptococcus agalactiae (Group B streptococcus, GBS) is highly adapted to humans,
where it is a normal constituent of the intestinal and vaginal flora. Yet, GBS has highly
invasive potential and causes excessive inflammation, sepsis, and death at the beginning
of life, in the elderly and in diabetic patients. Thus, GBS is a model pathobiont that thrives
in the healthy host, but has not lost its potential virulence during coevolution with mankind.
It remains incompletely understood how the innate immune system contains GBS in the
natural niches, the intestinal and genital tracts, and which molecular events underlie break-
down of mucocutaneous resistance. Newborn infants between days 7 and 90 of life are at
risk of a particularly striking sepsis manifestation (late-onset disease), where the transition
from colonization to invasion and dissemination, and thus from health to severe sepsis is
typically fulminant and not predictable. The great majority of late-onset sepsis cases are
caused by one clone, GBS ST17, which expresses HvgA as a signature virulence factor and
adhesin. In mice, HvgA promotes the crossing of both the mucosal and the blood–brain
barrier. Expression levels of HvgA and other GBS virulence factors, such as pili and tox-
ins, are regulated by the upstream two-component control system CovR/S. This in turn is
modulated by acidic epithelial pH, high glucose levels, and during the passage through the
mouse intestine. After invasion, GBS has the ability to subvert innate immunity by mecha-
nisms like glycerinaldehyde-3-phosphate-dehydrogenase-dependent induction of IL-10 and
β-protein binding to the inhibitory phagocyte receptors sialic acid binding immunoglobulin-
like lectin 5 and 14. On the host side, sensing of GBS nucleic acids and lipopeptides by both
Toll-like receptors and the inflammasome appears to be critical for host resistance against
GBS.Yet, comprehensive models on the interplay between GBS and human immune cells
at the colonizing site are just emerging.
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INTRODUCTION
Streptococcus agalactiae, Group B Streptococcus (GBS), is a com-
mensal of the human intestinal and vaginal tract in 15–30% of
healthy adults, but remains one of the most important invasive
pathogens in newborn infants and the elderly (1–4). Every 10th
neonate acquires GBS vertically during passage through the birth
canal or shortly thereafter. In most cases, GBS can be assumed to
become a normal constituent of the child’s microbiome. In other
cases, other colonizing bacteria that expand on the expense of GBS
may replace it. These dynamic processes early in life are generally
safe, as 99% of at least temporarily colonized infants will never
develop invasive GBS disease (5–8). The achievement of establish-
ing a microbiome including GBS can best be judged in light of GBS
late-onset diseases (LOD) and meningitis: if GBS does not adapt, it
may cause fulminant disease. Notably, crossing the intestinal bar-
rier and the blood barrier seems to be mechanistically linked. GBS
serotype III, a particularly frequent isolate in neonatal meningitis,
has recently been found to exhibit specific neurotropism through
expression of the adhesion factor HvgA (9, 10). HvgA efficiently
supports bacterial adhesion and transfer through to the intesti-
nal wall and later across the blood–brain barrier, specifically the
vascular endothelium and the choroid plexus (9). In other words,
protection of the neonatal brain from GBS starts in the gut. Long-
term neurological impairment of variable degree, which affects
about 35–50% of infants surviving meningitis, has become par-
ticularly important in the Western world, where improvements
in intensive care have decreased lethality of GBS invasive disease
below 10% (9, 11).
By definition, GBS is a normal constituent of the “intestinal
microbiota,” which comprises numerous bacteria, fungi, and pro-
tozoa. In a normal adult, the microbiota comprises more than
10,000 species, adding up to 1500 g in biomass. The composi-
tion of the microbiota is unique to the host and can be viewed
as a personal fingerprint that emerges in early infancy (12, 13).
Members of the bacterial phyla Bacteroidetes, Firmicutes (e.g., Lac-
tobacillus and Clostridum spp), Proteobacteria, Actinobacteria (e.g.,
www.frontiersin.org October 2014 | Volume 5 | Article 519 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Landwehr-Kenzel and Henneke GBS: from colonization to disease
Bifidobacterium spp.), Fusobacteria, and Spirochaetes are the most
important constituents of the gastrointestinal flora (12, 14, 15).
Notably, the microbial composition underlies temporal changes
during the first year of life and differs between children born vagi-
nally and by caesarian section (16–18). A modulating role of breast
milk feeding in the composition of the neonatal microbiome, e.g.,
by maternal secretory IgA, antimicrobial peptides, lactoferrin, and
sCD14, has been shown by several investigators (19–25). In twins,
it appears that both genetic and environmental factors contribute
to the composition of the intestinal microbiota (22, 26, 27).
Colonizers of the human intestine are generally considered as
“symbionts” that stabilize the intestinal homeostasis by acidifica-
tion of the intraluminal milieu, maintenance of the transepithelial
resistance, prevention of pathogen adherence, and continuous
immune stimulation (28–32). Pathobionts are potentially path-
ogenic colonizers that usually reside in the intestine in coexistence
with the host,but can cause severe local or systemic disease. In new-
born infants, the most important examples are E. coli, enterococci,
and GBS. The Janus face of GBS is underlined by the fact that 10%
of all neonates are at least temporarily colonized by GBS (1–4),
yet only 1% of these develops invasive disease (5–8). Beginning at
birth, GBS colonization rates continuously increase to 20–30% in
adults (1–4). This indicates that GBS transmission occurs not only
perinatally, but also horizontally later in life. Next to the exposure
to various bacterial strains, external factors like stress, drugs, diet,
gastrointestinal infections, and endogenous factors, like diabetes,
alter the composition of the intestinal microbiota (21, 33). These
individual life style and health factors may explain in part,why GBS
is an important cause of soft-tissue and urinary tract infections,
arthritis, and sepsis in patients >65 years and those with chronic
diseases such as stroke (OR 3.5), diabetes (OR 3.0), kidney or liver
(OR 9.7) failure, and cancer (breast cancer OR 4.0) (34). In healthy
adults, GBS predominantly colonizes the outer mucus layer of the
colon, yet may occasionally reside in the small intestine as well (35,
36). In pregnant women, GBS is a frequent cause of urinary and
upper genital tract infections, intra-amniotic infections, and sepsis
(37, 38). Whether GBS colonization usually, i.e., in infants as well as
adults, starts in the intestinal tract and expands from there to other
sites, or whether GBS subsets develop at independent colonization
sites of the same human influenced by the site-specific microen-
vironment, has not yet been clarified. Accordingly, the origin of
differences in serotype distribution between non-pregnant adults
with invasive disease, where serotype V contributes to almost 30%
of cases, and pregnant women or newborn infants, where serotypes
III and Ia predominate, is not well understood (7, 39, 40).
THE PATHOGEN SITE: GBS VIRULENCE STRATEGIES TO
PROGRESS FROM COLONIZATION TO DISEASE
What can we learn from neonatal GBS sepsis models with respect
to factors regulating colonization and invasion? GBS sepsis in new-
born infants can be divided into early-onset disease (EOD), which
occurs within the first week of life by vertical GBS transmission
during delivery, and LOD, which occurs through vertical or hori-
zontal transfer and manifests between day 7 and 3 months of age
(41). However, since more than 90% of all EOD cases manifest as
sepsis, pneumonia, or meningitis within the first 24–48 h of life,
some authors limit early-onset sepsis to the first 72 h after birth (40,
42). Peripartum antibiotic prophylaxis has markedly decreased the
incidence and case fatality rate of EOD; the incidence or clinical
course of LOD, however, has remained largely unaffected. The
clinical picture of LOD typically manifests as hyperinflamma-
tory syndrome with meningitis. As outlined above, GBS serotype
III is greatly overrepresented in LOD, with clonotype ST17 con-
tributing up to 90% of all clinical isolates found in meningitis
(as compared to colonizing strains). This led to the phenotypic
description of GBS III ST17 as hypervirulent clone (43–47). A
recently published longitudinal study found that in LOD, GBS
and other bacteria isolated from the blood of preterm infants
genetically matched clones previously found in the patients’ stool
(48). Accordingly, in many cases, LOD likely results from systemic
spread of intestinal GBS, and not directly from vertical or horizon-
tal transmission. Nevertheless, postnatal exposure with maternal
GBS III ST17, e.g., via breast milk, appears to underlie some sepsis
cases (49).
For the development of sepsis by GBS spreading from the
intestine, the bacterium has to undertake three consecutive steps:
(i) colonization of the colon and potentially the small intes-
tine, (ii) translocation across the intestinal epithelium, and (iii)
immune evasion preventing GBS clearance from the blood stream
(summarized in Table 1).
The first and pivotal step in GBS colonization is adhesion.
Adhesion factors are expressed on the bacterial surface and allow
GBS to bind to extracellular matrix proteins and epithelial cells of
the colon and the genital tract resulting in biofilm formation (50,
51). Adhesion factors can additionally promote invasion, either
by disruption of the epithelial cell layer or by modulation of the
epithelial cytoskeleton and the junctional protein assembly, which
in turn allows for paracellular translocation (52–55).
Two adhesion factors mediate attachment to the extracellu-
lar matrix. They are named according to their specific ligand:
(i) fibrinogen-binding proteins and (ii) laminin-binding pro-
teins (Lmb). While fibrinogen-binding protein A (FbsA) pro-
motes adhesion, fibrinogen-binding-protein B (FbsB) mediates
GBS invasion into host cells. FbsA and FbsB bind to both immo-
bilized and soluble fibrinogen (56, 57). Bacterial attachment to
extracellular matrix via Lmb seems important for GBS transloca-
tion across the intestinal epithelium and the blood–brain barrier
(58, 59). Furthermore, the GBS surface adhesin BsaB binds to
fibronectin (60). However, whether BsaB contributes to GBS inva-
sion or mainly promotes colonization with GBS via its biofilm
enhancing effects has not been fully resolved, yet.
Another group of GBS adhesion factors is characterized by the
highly conserved LPxTG (Leu–Pro–X–Thr–Gly) motif at the C-
terminus (61). GBS LPxTG is cleaved between Thr and Gly by the
transpeptidase Sortase A, which covalently binds GBS to the cell
wall and thus promotes both colonization and invasion (62). The
first group of the LPxTG containing adhesion factors is the family
of Alpha C proteins, which are encoded by the bca (group B, C pro-
tein alpha) gene and expressed on most strains of serotype Ia, Ib,
and II (63). Alpha C proteins are further characterized by long tan-
dem repeating elements, which allow antigenic variations, and a
conserved N-terminal domain, encoding 185 amino acids (61, 64–
67). GBS isolated from mothers who recently delivered a child with
invasive GBS disease show increased expression of alpha C protein
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Table 1 | GBS virulence factors and their role in transition from colonization to invasive disease.
Mechanism
Virulence factor
Colonization Adhesion Invasion 
Immune
evasion 
Neurotropism
Fibrinogen binding protein A (FbsA) + + 
Fibrinogen binding protein B (FbsB) + 
Laminin binding protein (Lmb) + + 
GBS surface adhesion (BsaB) + + (+) 
Alpha C proteins (ACP) + + + + 
Serine rich repeat proteins (Srr) + + + 
Pili + + + + + 
Hypervirulent GBS adhesiin (HvgA) + + + (+) + 
ß-hemolysin/cytolysin (ß-H/C) + + + + + 
Capsular polysaccharides (CPS) + 
Streptococcal C5a peptidaseof GBS (ScpB) + 
GBS immunogenic bacteria adhesion (BibA)  + 
Factor H + 
IgA-binding beta-antigen + 
D-alanylation + 
Superoxide dismutase (SodA) + 
tandem repeats (“aa”). This is associated with increased suscepti-
bility to opsonophagocytic antibody-mediated killing as compared
to the GBS isolated previously from the respective newborn infant
with sepsis (67). In line with these observations, low tandem repeat
expression during infections seems to impair the specific antibody
response and antibody-mediated killing (61, 64, 65, 68, 69). Fur-
thermore, GBS alpha C proteins can promote invasion of human
epithelial cells via α1β1-integrin binding (66).
The second group of LPxTG containing adhesion factors are
serine-rich repeat (Srr) proteins, which interact with human ker-
atin (Srr-1) and which enhance GBS virulence in mice (Srr-2) (70).
Only recently, fibrinogen has been identified as Srr binding part-
ner (71). Interestingly, while highly virulent serotype III strains
express Srr-2 (70, 71), other GBS strains express Srr-1 (serotype
Ia, Ib, Ic, II, and V).
Additional structures involved in adhesion are Pili, which were
first described in GBS in 2005 (72). Pili promote colonization of
epithelial cell surfaces, support biofilm formation, and facilitate
translocation across the blood–brain barrier (51). They consist
of a major shaft subunit, the backbone protein BP, which is crit-
ical for pilus assembly, and the two ancillary proteins AP1 and
AP2 (73). Three pilus islands (PI1, PI2a, and PI2b) were identi-
fied. In mice, PI2a is essential for GBS virulence (74), and pilus
island specific antibodies enhance opsonophagocytic killing and
protect from sepsis (75, 76). Yet, development of pilus structures
as vaccine candidates was hampered by variable pilus expression
in GBS (75, 76).
Comparative expression analysis between clones with different
clinical virulence (based on the disease phenotype in infants) led
to the identification of the surface-anchored hypervirulent GBS
adhesin (HvgA) as a specific virulence factor in GBS ST17 (9).
Similar to pili, HvgA mediates both colonization and invasion
in the intestine and confers meningeal tropism in neonatal mice
(9, 10). Interestingly, GBS isolated from blood and cerebrospinal
fluid during invasive disease express higher HvgA levels as com-
pared to GBS cultured in vitro, indicating upregulation of HvgA
expression during infection (9). Moreover, the ability of GBS ST17
to spread from the intestinal lumen is linked to the age of the
mice, since 60–70% of preweaning mice (15–21 days old) suc-
cumb after enteral infection with hvgA-expressing GBS, whereas
mice ≥4 weeks are protected (9). An experiment of nature, which
we recently observed, suggests that yet to be identified changes in
GBS virulence likely contribute to sepsis onset. An HvgA-positive
strain of GBS, which was transmitted probably through breast
milk from the mother, induced two episodes of sepsis each in
twins, i.e., a total of four episodes, in a synchronous fashion. In
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all cases, sepsis started with soft-tissue infections of the lower oral
cavity border, which implies a temporarily highly invasive and
reproducible behavior of GBS (49).
Group B Streptococcus translocation across the epithelial barrier
is further facilitated by the virulence factor β-hemolysin/cytolysin
(β-H/C) (77–79). β-H/C induces cytolysis in eukaryotic cells and
promotes bacterial invasion across epithelial and endothelial walls,
including the blood–brain barrier. In mice,β-H/C induces placen-
tal inflammation and preterm birth, independently of bacterial
ascension (80). β-H/C-deficient GBS show impaired virulence in
various in vivo models including pneumonia, sepsis, and meningi-
tis (77, 79, 81). However, at sublytic concentrations, β-H/C drives
expression of the anti-inflammatory cytokine IL-10 and inhibits
both IL-12 and NOS2 expression in GBS-infected macrophages
(82). Thus expression levels of β-H/C appear to determine whether
GBS stabilizes its niche to allow for colonization, or whether
GBS becomes invasive. Additionally, the pore-forming toxin and
co-hemolysin CAMP factor may contribute to GBS pathogene-
sis under certain circumstances (83, 84), but is dispensable for
systemic virulence (83–86).
Distinct types of capsular polysaccharides (CPS), which under-
lie the serotyping system, allow for immune evasion, since α2→ 3
linked sialic acid modifications use molecular mimicry with host
sugar epitopes. Direct binding to immunoglobulin-like lectins
(Siglecs) on leukocytes inhibits complement C3 activation on the
bacterial surface (87–89). Complement inactivation is further sup-
ported by ScpB (Streptococcal C5a peptidase of GBS)-mediated
proteolytic C5a inactivation (90) and reduced complement bind-
ing through the inhibitory factors BibA (GBS immunogenic bac-
terial adhesin) (91) and factor H (92). Immunoglobulin binding,
an essential precondition for opsonophagocytosis, is hampered by
the IgA-binding beta-antigen of the c protein complex, which rec-
ognizes the Fc region of human immunoglobulin A (93). GBS
evades phagolysosomal processing by neutralizing reactive oxygen
species via BibA, β-H/C, superoxide dismutase (SodA), and addi-
tional unknown factors (77, 78, 91, 94–96). Similarly, binding of
intestinal and circulating antimicrobial peptides can be suppressed
by intrinsic GBS mechanisms such as d-alanylation of lipteichoic
acid, which is catalyzed by the dlt operon. Down-modulation of
d-alanylation decreases the negative surface charge, which in turn
is important for cationic binding of antimicrobial peptides such
as colistin (97).
REGULATION OF GBS VIRULENCE
As outlined above, the human intestine is the natural niche for
GBS. In other words, GBS thrives in healthy hosts. Accordingly,
it is for the benefit of both GBS and the host if GBS is kept
in a colonization state and does not exhibit its aggressive traits.
Thus, expression of virulence factors in GBS must be tightly reg-
ulated. Two-component control systems, which typically consist
of a membrane-linked histidine kinase sensor and a cytoplasmatic
transcriptional element, are common in bacteria and more than
4000 regulatory systems have been described (98, 99). In GBS,
CovS/CovR (Control of virulence Sensor/Regulator) tightly reg-
ulates the expression of pili, BsaB, hvgA, cyIE, which is involved
in β-H/C expression, and many other genes (60, 100, 101). CovS
acts as a pH sensor. In an acidic milieu, such as the vagina, CovS
remains in an autophosphorylated state and activates the reg-
ulatory domain CovR by transphosphorylation at the aspartate
residue D53. Subsequently, the phosphorylated form of CovR acts
as a repressor. An increase in pH reduces CovS phosphorylation
and induces the expression of β-H/C (102). In addition to pH, high
glucose levels, peripheral insulin resistance, and passage through
the intestine modulate CovR/CovS in mice (103–105). Inactiva-
tion of the CovR system increases GBS adherence to epithelial
cells (106) by upregulation of PI1 expression (104). In line with
this, GBS mutant in either CovS or CovR show increased hemolysis
and approximately 80-fold upregulated HvgA (9).
Next to CovS, the serine/threonine kinase Stk1 acts as a sensor
for environmental stimuli. Stk1 activation leads to phosphory-
lation of CovR at threonine 65. GBS with Stk1 mutations show
reduced expression of β-H/C; susceptibility to opsonophagocytic
killing and oxidative stress is increased (107, 108). Thus, while
CovR phosphorylation at the aspartate residue D53 by CovS leads
to protein activation associated with reduced virulence, Stk1-
mediated phosphorylation at the threonine residue T63 increases
the expression of β-H/C (108). Abx1, an additional partner within
the CovS/CovR system, displays complex counterbalancing activ-
ity (107–109). As transmembrane protein Abx1 holds direct prox-
imity to CovS, which it partially antagonizes. Both functional loss
and overexpression of Abx1 hampers GBS virulence expression,
and Abx1 expression itself is critically dependent on functional
β-H/C formation (109). This system “fine tunes” GBS and may
explain, at least in part, the loss of virulence of hyperhemolytic
mutants due to CovR inactivation or Abx1 overexpression.
In summary, the CovS/CovR system inhabits a central role in
the control of GBS virulence. It is tightly regulated, and specific
environmental factors allow for subtle adaptation of the bacterial
phenotype to the site of colonization/infection.
THE HOST SITE: TOLL-LIKE RECEPTORS AND THE
INFLAMMASOME MEDIATE HOST RESISTANCE AND FATAL
INFLAMMATION
Neonatal mice are exquisitely sensitive for GBS. Less than 100
bacteria injected s.c. constitute the lethal dose 90%. Under these
conditions, disease is at least partially immune mediated, since
the inflammatory cytokine TNF alone accounts for approximately
half of the deaths (110). An important ligand receptor inter-
action resulting in TNF formation is that between diacylated
lipoproteins and Toll-like receptors (TLR)2/6 heterodimers (111).
Deletion of the diacyl transferase Lgt from GBS results in the
same change in GBS sepsis phenotype as that observed in conven-
tional TLR2 knock-out mice. The TLR-dependent recognition of
bacterial lipopeptides can be assumed to primarily occur on the
cell surface (112), although endosomal recognition of lipopep-
tides has recently been demonstrated (113). Next to lipoproteins,
nucleic acids from GBS potently activate inflammatory genes in
phagocytes. At least three distinct signaling pathways engaged by
GBS nucleic acids have been identified. First, intracellular recog-
nition of GBS DNA by one or several currently unknown cytosolic
receptors results in the formation of type I interferons in a TBK1
and IRF3-dependent fashion (114) (IFN pathway). Second, two
pathways involve recognition of GBS RNA. The first engages
an UNC-93B- and MyD88-dependent pathway (115, 116) (TLR
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pathway), which has been shown to utilize TLR7 in dendritic
cells (117), whereas the cognate TLR in macrophages is still elu-
sive (116). The second pathway involves cytosolic sensing of RNA
and β-hemolysin through the intracellular NLRP3 inflammasome
(NOD-like receptor family, pyrin domain containing 3), which
mediates IL-1β maturation in macrophages and dentritic cells
(118, 119). Accordingly, in a mouse GBS sepsis model, NLRP3-
deficiency is associated with significantly increased lethality (118,
119). It appears that NLRP3 and GBS RNA closely interact in the
cytosol, and disruption of the GBS bearing phagosomes allows
NLRP3 and GBS RNA to get into close contact (118). Discrimina-
tion of bacterial RNA from human ribosomal and transfer RNA
appears to depend at least partially on the RNA methylation status
(120). In S. aureus, methylated ribosomal RNA is recognized by
TLR13, a TLR that currently lacks a human homolog. Accordingly,
S. aureus strains that have acquired the methylase erm, confer-
ring erythromycin resistance, have lost their TLR13-activating
potential (121).
In summary, sensing of GBS lipoproteins and nucleic acids
mediates activation of macrophages and dendritic cells and con-
tributes to resistance against GBS and disease progression during
sepsis. Yet, the contribution of these systems to containing GBS at
mucosal sites is currently unclear.
IL-10 AND ITS ROLE IN GBS COLONIZATION AND DISEASE
Very recently, the glycolytic enzyme glycerinaldehyde-3-
phosphate-dehydrogenase (GAPDH) from GBS was shown to
subvert immunity by inducing IL-10 (103, 122, 123). This adds to
the kaleidoscope of functions of an enzyme, which is largely known
for its role in bacterial energy generation (124–127) (summarized
in Figure 1). GBS GAPDH is expressed as a surface molecule
and in a soluble form (126, 128, 129). In mice, it directly acti-
vates B- and, to a lower extent, T-lymphocytes and induces the
maturation of anti-GAPDH Ig-secreting plasma cells (130). Both
endogenous and systemically administered GAPDH specific anti-
bodies significantly reduce intestinal GBS colonization and protect
from invasion of GAPDH-expression GBS strains. On the other
hand, administration of recombinant GAPDH induces systemic
release of IL-10 in mice and increases susceptibility to invasive
GBS disease and bacterial invasion of per se non-invasive strains
(82, 122, 130, 131). In line with these observations, IL-10-deficient
mice are protected from invasive GBS disease and show improved
survival in various sepsis models (122, 131–133). These effects are
further consistent with the observation that reduced IL-10 activ-
ity increases neutrophil recruitment and bacterial killing (122,
130, 131). However, in earlier investigations, IL-10 given before
infection protected neonatal mice from GBS sepsis and correlated
FIGURE 1 | GBS transition to invasive disease. GBS lipoproteins, GAPDH,
and nucleic acids majorly contribute to intestinal immune activation inducing
pro-inflammatory responses, neutrophil recruitment, cellular proliferation,
maturation and, finally, microbial clearance. Early induction of specific
antibody release by B plasma cells and IL-10 secretion by both B-lymphocytes
and phagocytes act as a negative feedback loop to counter-regulate
hyperinflammation. Uncontrolled increase of IL-10, in contrast, hampers
neutrophil recruitment and bacterial elimination. At the same time,
T-lymphocytes can directly interact with GBS ligands or receive
pro-inflammatory signals via monocytic cytokines. While Th1 and Th17 cells
promote infection control, activation of regulatory T cells prevents
hyperinflammation and supports post-infectious healing.
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with TNF suppression and improved survival (134). This effect
was strictly dependent on the time of IL-10 application, since
simultaneous or post-infectious administration failed to mediate
protective effects. In contrast, in LPS-TLR4 induced septic shock
models IL-10 improved survival even when given simultaneously
with or early after LPS administration (133, 135, 136). Mono-
cytes, macrophages, and T- and B-lymphocytes are all sources
of IL-10 (Figure 1). IL-10 induction in macrophages depends
on JNK signaling, which in turn is critical for the outcome in
GBS sepsis (137–140). Expression of IL-10R (IL-10 receptor) and
TGFBR1/TGFBR2 (TGF-beta receptors 1 and 2) and the presence
of their specific ligands are pivotal to preserve immune home-
ostasis (141–144). In vitro, IL-10 reduces NF-kB signaling and
the expression of TLRs, MyD88, and TIR in resident intestinal
macrophages (iM) and circulating monocytes (145). In neonatal
mice, the inflammatory program of iM is shifted toward IL-10 as
the signature effector molecule via TGF-beta as a signaling inter-
mediate (146). Patients with defects in the IL-10 or IL-10R gene
develop severe, early-onset inflammatory bowel disease. Thus IL-
10 is critical for intestinal inflammation control (147–149). Since,
mice with a targeted deletion of STAT3 in macrophages and neu-
trophils (LysMcre/Stat3flox/−) develop spontaneous enterocolitis,
it seems that tissue macrophages constitute the major source of
IL-10 (150). Macrophage expression of IL-10 is dependent on
TLR-dependent sensing of the microbiota and signal transduction
by the adapter protein MyD88 (151). The multitude of functions of
IL-10, its site-specific functions and the dynamics in its inducible
effects all contribute to its highly complex role in stabilizing the
interface between GBS and host.
GBS IN (TRANSIENT) IMMUNODEFICIENCY
The so-called human model, where patients with monogenetic
variations provide clues for the role of cell specific immunity,
has been powerful in better understanding host–microbe interac-
tions leading to coexistence and disease. An intriguing example
is MyD88/IRAK-4-deficiency with its specific susceptibility to
staphylococci, streptococci, and Pseudomonas spp. However, the
search for monogenetic immunodeficiency disorders underlying
susceptibility to invasive GBS infections has only been partially
successful so far. One patient with very late-onset GBS sepsis suf-
fering from IRAK-4 deficiency has been reported, supporting that
cellular innate immunity and the TLR system are important for
resistance against GBS (152–154). It can be expected that whole
exome or genome analysis in families with GBS sepsis will provide
further information in this regard in the future.
Next to the genetic absence of specific factors in cellular innate
immunity, transient changes in innate immunity may underlie
susceptibility to invasive GBS disease in newborn infants. Neona-
tal sepsis is characterized by excessive inflammation, since high
levels of pro-inflammatory cytokines can be measured in the
serum of newborn infants suffering from invasive GBS disease.
In vitro, PBMC from healthy neonates rapidly respond to GBS
with the formation of large amounts of IL-6, TNF, IL-8, and IL-
1β (155–157). Since insulin suppresses the cytokine formation in
response to GBS, peripheral insulin resistance present in newborn
infants and particularly during sepsis may promote the inflamma-
tory process (158). Excessive stimulation of immune cells may be
further enhanced by a reduction of antimicrobial phagocyte prop-
erties, which are markedly impaired in neonates and may allow for
pathogen persistence and failure to contract the immune response
(159–161). GBS persistence likely results from reduced G-actin
polarization and L-selectin expression in newborn, especially
preterm infants, which results in impaired neutrophil adhesion
and migration (162, 163). Moreover, low expression of opsoniz-
ing complement components, immunoglobulins, reactive oxygen
species, the integrin CD11b/CD18, and Fc-gamma receptors II and
III (164–166) and a predominant polarization of T-lymphocytes
toward Th2 and Th17 may overall interfere with timely and rig-
orous clearance of invasive GBS (161, 167–173). How can the
high levels of IL-10 in neonatal GBS infections, as observed in
mice (174–177) and humans (178–180), be explained in view of
the generally highly inflammatory state? Although conclusive evi-
dence on this matter is lacking, it is tempting to speculate that
the negative impact of IL-10 on neutrophil function, which allows
for pathogen expansion, overrides the direct anti-inflammatory
properties of IL-10 on the mononuclear phagocyte system. In this
scenario, the net result in neonatal GBS sepsis is inflammatory
despite high IL-10 levels.
CONCLUSION
Group B Streptococcus comprises several regulatory systems that
respond to the microenvironment and, by steering adhesion and
virulence factors, allow for colonization of mucosal niches in the
genital and (lower) intestinal tract. Colonization is further prop-
agated by the GBS-intrinsic ability to manipulate local cellular
immunity. Yet, under only partially understood conditions GBS
looses its colonizing trait and invades the host. Then, immune
mechanisms that usually stabilize the natural GBS niche may lead
to detrimental immunopathology. Rather subtle changes on the
single immune cell level in newborn infants appear to facilitate
the escalation from a beneficial site-specific response to sepsis and
meningitis. Better understanding of the dynamic expression of vir-
ulence traits in GBS, and of the cellular immunology that shapes
the GBS niche, will hopefully pave the way for preventing livelong
disabilities inflicted by a normal component of the microbiota.
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